PeerView Clinical Pharmacology CME/CNE/CPE Video - April W. Armstrong, MD, MPH / Kenneth B. Gordon, MD - Taking Aim at the TYK2 Pathway in Psoriasis: Addressing Unmet Treatment and Patient Needs With an Innovative Therapeutic Approach

April W. Armstrong, MD, MPH / Kenneth B. Gordon, MD - Taking Aim at the TYK2 Pathway in Psoriasis: Addressing Unmet Treatment and Patient Needs With an Innovative Therapeutic Approach

09/30/21 • 58 min

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/TWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in psoriatic disease offer learners an in-depth look at the complex pathophysiology of psoriasis, current management paradigms, and challenges in the care of patients with moderate to severe disease. Upon completion of this accredited CE activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with moderate to severe psoriasis, Discuss the rationale for blocking the JAK-STAT pathway with small molecules as a treatment approach to psoriasis, Compare and contrast novel JAK inhibitors for the treatment of psoriasis in the context of selectivity, efficacy, and safety, Treat psoriasis in accordance with current evidence and guidelines, identifying patients with moderate to severe disease, who would likely derive benefit from novel nonbiologic oral therapeutic options.

Previous Episode

undefined - Jamie E. Chaft, MD - Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung Cancer: Latest Data Informing Best Practices for Multimodal Management of Stage I-III NSCLC

Jamie E. Chaft, MD - Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung Cancer: Latest Data Informing Best Practices for Multimodal Management of Stage I-III NSCLC

Go online to PeerView.com/CBB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immunotherapy revolution in lung cancer continues, as clinical practice and research build on achievements made in advanced NSCLC and aim to extend the benefits of immunotherapies to earlier stages. Immune checkpoint inhibitor (ICI) therapy is routinely used as consolidation following chemoradiation for patients with stage III unresectable NSCLC. Now, ICIs and rational combinations are starting to show promising activity as neoadjuvant and adjuvant therapies for patients with resectable stage I-III NSCLC as well. Optimal approaches are still being determined, and many questions and controversies remain, but it is essential for oncologists, thoracic surgeons, and other multidisciplinary specialists to work together to make these therapies available to patients with earlier stages of lung cancer. This PeerView educational activity, based on a recent web broadcast, provides essential updates on the evolving science supporting the use of ICIs in multimodal treatment of unresectable and resectable stage I-III NSCLC. Multidisciplinary perspectives on how to make the most of immunotherapies and rational combinations in curative-intent settings are shared as well. Upon completion of this accredited CE activity, participants should be better able to: Characterize the rationale for using immunotherapy as a component of multimodal therapy in locally advanced or earlier stages of non–small cell lung cancer (NSCLC), Review key clinical trials and available efficacy/safety data on immunotherapies and immune-based combinations in locally advanced and earlier stages of NSCLC, Determine the best assessment and treatment approaches for diverse populations of patients with stage I-III NSCLC as part of clinical practice or clinical trials based on the latest evidence and recommendations, effective multidisciplinary and interprofessional collaboration and care coordination, and patient needs, values, and preferences.

Next Episode

Sanam Loghavi, MD - Secondary AML Through the Microscope: A Pathology-Informed Guide to Modern Diagnostic and Treatment Principles

Go online to PeerView.com/SFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert pathologist discusses secondary acute myeloid leukemia (AML) as well as the modern tools used in diagnostic assessment that can help facilitate appropriate risk stratification and collaborative treatment decisions so therapies beyond conventional chemotherapy options can be considered. Upon completion of this accredited CE activity, participants should be better able to: Summarize clinical, molecular/genetic, and pathologic features of secondary AML/AML-MRC that can be used to confirm a diagnosis and distinguish this disorder from other subtypes, Describe the testing tools and methods that can be used to capture the morphologic and molecular features of secondary AML/AML-MRC, Cite efficacy and safety evidence surrounding the use of novel therapeutics in patients with secondary AML, Develop a diagnostic and risk-stratification strategy in consultation with treating clinicians once a diagnosis of AML is suspected so a definitive diagnosis of secondary AML can be rendered and appropriate therapies can be selected.